https://www.selleckchem.com/products/rmc-4630.html
ter therapy]) occurring in 40.9%, class II (oligoprogressors [≤3 lesions at recurrence]) occurring in 36% (including 7.9% of patients with PSA recurrence but no metastatic disease), and class III (polyprogressors [3 lesions]) occurring in 23.1% of patients. After MDT, the majority of patients have long-term control or oligoprogression (class I or II). Recurrence tended to occur in osseous sites. These findings, if validated, have implications for future integration of MDT and clinical trial design. After MDT, the majority of patien
Gefällt mir
Kommentar
Teilen
